RadNet (RDNT) Stock Rating Upgraded by BidaskClub
BidaskClub upgraded shares of RadNet (NASDAQ:RDNT) from a sell rating to a hold rating in a report issued on Saturday morning.
Several other analysts have also recently issued reports on RDNT. Zacks Investment Research cut RadNet from a hold rating to a sell rating in a research report on Wednesday, October 4th. TheStreet cut RadNet from a b- rating to a c rating in a research report on Friday, October 27th.
Shares of RadNet (NASDAQ:RDNT) opened at $10.15 on Friday. The company has a debt-to-equity ratio of 7.88, a current ratio of 1.29 and a quick ratio of 1.29. The company has a market capitalization of $483.38, a PE ratio of 44.13, a price-to-earnings-growth ratio of 2.31 and a beta of 0.83. RadNet has a 1 year low of $5.25 and a 1 year high of $11.90.
In related news, EVP Norman R. Hames sold 5,000 shares of the stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $9.96, for a total transaction of $49,800.00. Following the completion of the sale, the executive vice president now owns 365,087 shares in the company, valued at $3,636,266.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John V. Crues sold 20,000 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $9.89, for a total value of $197,800.00. The disclosure for this sale can be found here. Insiders have sold 133,084 shares of company stock valued at $1,321,587 in the last quarter. 9.36% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its stake in RadNet by 7.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,531,850 shares of the medical research company’s stock valued at $11,872,000 after buying an additional 112,194 shares during the last quarter. Vanguard Group Inc. boosted its stake in RadNet by 4.2% during the second quarter. Vanguard Group Inc. now owns 1,284,852 shares of the medical research company’s stock valued at $9,957,000 after buying an additional 51,229 shares during the last quarter. State Street Corp boosted its stake in RadNet by 9.2% during the second quarter. State Street Corp now owns 585,218 shares of the medical research company’s stock valued at $4,538,000 after buying an additional 49,186 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in RadNet by 85.7% during the third quarter. JPMorgan Chase & Co. now owns 503,880 shares of the medical research company’s stock valued at $5,795,000 after buying an additional 232,524 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in RadNet by 5.2% during the second quarter. Northern Trust Corp now owns 436,407 shares of the medical research company’s stock valued at $3,382,000 after buying an additional 21,746 shares during the last quarter. 53.16% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “RadNet (RDNT) Stock Rating Upgraded by BidaskClub” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/radnet-rdnt-stock-rating-upgraded-by-bidaskclub/1800729.html.
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.